Enzyme replacement therapy with galsulfase for mucopolysaccharidosis type VI-Reference-Cited by-同舟云学术

Enzyme replacement therapy with galsulfase for mucopolysaccharidosis type VI

Published:2021-09-17 Issue:9 Volume:2021 Page:
ISSN:1465-1858
Container-title:Cochrane Database of Systematic Reviews
language:en
Short-container-title:

Author:

Brunelli Marcela Junqueira¹,Atallah Álvaro N²,da Silva Edina MK³

Affiliation:

1. Universidade Federal de São Paulo; São Paulo Brazil

2. Cochrane Brazil; Centro de Estudos de Saúde Baseada em Evidências e Avaliação Tecnológica em Saúde; São Paulo Brazil

3. Emergency Medicine and Evidence Based Medicine; Universidade Federal de São Paulo; São Paulo Brazil

Publisher

Wiley

Subject

Pharmacology (medical)

Reference42 articles.

1. Enzyme replacement therapy for mucopolysaccharidosis VI: long-term cardiac effects of galsulfase (Naglazyme®) therapy;Braunlin;Journal of Inherited Metabolic Disease,2013

2. A phase 3, randomized, double-blind, placebo-controlled, multicenter, multinational clinical study of recombinant human N-acetylgalactosamine 4 sulfatase (rhASB) in patients with mucopolysaccharidosis VI [abstract];Guffon;Journal of Inherited Metabolic Disease,2005

3. Enzyme replacement therapy for mucopolysaccharidosis VI: a phase 3, randomized, double-blind, placebo-controlled, multinational study of recombinant human N-acetylgalactosamine 4-sulfatase (recombinant human arylsulfatase B or rhASB) and follow-on, open-label extension study;Harmatz;Journal of Pediatrics,2006

4. Long term benefit and safety with recombinant human arylsulfatase B (rhASB) ERT for MPS VI [abstract];Harmatz;Journal of Inherited Metabolic Disease,2006

5. Long-term follow-up of endurance and safety outcomes during enzyme replacement therapy for mucopolysaccharidosis VI: final results of three clinical studies of recombinant human N-acetylgalactosamine 4-sulfatase;Harmatz;Molecular Genetics and Metabolism,2008

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Case study of two Iraqi patients with Mucopolysaccharidosis (Hurler syndrome "type I" and Maroteaux-Lamy syndrome "type VI") treated with Hematopoietic Stem Cell Transplantation (HSCT);Al Mustansiriyah Journal of Pharmaceutical Sciences;2023-01-15

2. Engineering a Therapeutic Protein to Enhance the Study of Anti-Drug Immunity;Biomedicines;2022-07-18